Fda Approves Risperidone Extended Release Injectable Option For Bipolar

Fda Approves Risperidone Extended Release Injectable Option For Bipolar Fda approves uzedy® (risperidone) extended release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar i disorder in adults.1. Fda approved risperidone extended release injectable for schizophrenia and bipolar 1 disorder, based on phase 3 trial results showing improved syndrome scale scores.

Fda Approves Risperidone Extended Release Injectable For Bipolar I The u.s. food and drug administration (fda) has now approved an expanded indication for risperidone (uzedy), a long acting injectable that offers a new maintenance treatment option for adults with bipolar 1 disorder. Fda approves uzedy® (risperidone) extended release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar i disorder in adults.1. The fda approved risperidone (uzedy; teva pharmaceuticals), a once monthly extended release injectable suspension, as either a monotherapy or an adjunctive therapy to lithium or valproate as a maintenance treatment in adults with bipolar i disorder. The fda approved uzedy for bipolar i disorder, expanding its use beyond schizophrenia, as a maintenance treatment option. uzedy is the first subcutaneous, long acting risperidone formulation, using steadyteq™ technology for controlled release.

Fda Approves Expanded Indication For Risperidone Extended Release The fda approved risperidone (uzedy; teva pharmaceuticals), a once monthly extended release injectable suspension, as either a monotherapy or an adjunctive therapy to lithium or valproate as a maintenance treatment in adults with bipolar i disorder. The fda approved uzedy for bipolar i disorder, expanding its use beyond schizophrenia, as a maintenance treatment option. uzedy is the first subcutaneous, long acting risperidone formulation, using steadyteq™ technology for controlled release. Fda approves uzedy® (risperidone) extended release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar i disorder in adults.1. Teva pharmaceuticals and medincell announced on october 10, 2025, the u.s. fda’s approval of an expanded indication for uzedy® (risperidone) extended release injectable suspension, now authorized for subcutaneous use as monotherapy or adjunctive therapy to lithium or valproate for maintenance treatment of bipolar i disorder (bd i) in adults. “adults living with bd i experience debilitating manic and depressive symptoms, and today’s fda approval of uzedy provides a new long acting formulation of risperidone that may help address. Fda approves uzedy® (risperidone) extended release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar i disorder in adults.1.